- Key Questions Answered:
- What are the key osteoporosis treatments?
- When will the late stage pipeline products launch, and how will it affect drug sales in the 7 major markets?
- Which unmet needs will remain unaddressed in the forecast period?
- What opportunities remain for pharmaceutical companies?
Changes are already being seen in the osteoporosis space, with the recent launch of Radius Health’s Tymlos (abaloparatide) in the US in 2017. Anabolic agents will continue to revolutionize the market, with the arrival of a novel sclerostin inhibitor, Evenity (romosozumab), and teriparatide biosimilars. Competition is expected to increase, driving down high price tags and potentially boosting the use of these therapies up the treatment paradigm.
Poor diagnosis rates, badly perceived drug side effects, and low compliance rates will continue to prove major hurdles for growth over the next 10 years.